ASCO 2012 Live Blog -- Sunday

CHICAGO ( TheStreet) --Welcome to TheStreet's live-blog coverage of the American Society of Clinical Oncology (ASCO) annual meeting. It's Sunday, the second full day of data presentations at the largest annual gathering of cancer drug researchers in the world.

On the schedule for today: ASCO's big plenary session, highlighting some of the most newsworthy clinical data at the conference. Roche ( RHHBY) and ImmunoGen ( IMGN) are in the plenary spotlight this year with data from the phase III study of T-DM1 in breast cancer. Also sharing the plenary stage is a study combining Roche's Rituxan with Teva's ( TEVA) Treanda in lymphoma.

Exelixis ( EXEL), Onyx Pharmaceuticals ( ONXX) and Celgene ( CELG) will also be presented data on Sunday.

Follow this live blog throughout the day for continuous updates and reports from the ASCO meeting. I'll be reporting on clinical data presentations as I see and hear them, and I'll be blogging from the hallways, exhibition hall and meeting rooms, giving you a real-time perspective on the investor-worthy buzz.

The blog will also capture tweets from a select and experienced group of analysts, doctors and journalists -- all of whom will add their perspective and insight into the ASCO meeting.

I welcome your comments and questions on this live blog, too, which I'll do my best to answer and publish as time permits.

--Written by Adam Feuerstein in Chicago.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

9 Stocks Goldman Sachs Thinks Will Blow Wall Street's Performance Away in 2019

9 Stocks Goldman Sachs Thinks Will Blow Wall Street's Performance Away in 2019

Jim Cramer on U.S.-China Trade: The Media Has it Wrong

Jim Cramer on U.S.-China Trade: The Media Has it Wrong

Is Tesla's Stock Set to Nearly Double to $500?

Is Tesla's Stock Set to Nearly Double to $500?

Tesla's $78,000 Model 3 Is a Bargain. Here's Why

Tesla's $78,000 Model 3 Is a Bargain. Here's Why